Fig. 6: Dose-dependent therapeutic efficacy of MD65. | Nature Communications

Fig. 6: Dose-dependent therapeutic efficacy of MD65.

From: Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

Fig. 6

Single doses of 1, 0.1, and 0.01 mg MD65 Ab/animal were administered at day 2 post viral infection. a Body weight profiles. b Kaplan–Meyer surviving curves. Curves describe mice treated with the indicated doses of MD65 (see color legend within panels) and control animals, administered with PBS (gray line). Data represent means ± SEM. Body weight change is displayed as the percentage of initial weight. Only data of the first 7 days are presented in the control group exhibiting significant mortality. In case of the mice treated with 0.01 mg MD65, the weight of the surviving animal is indicated by hollow circles and dashed line.

Back to article page